Immune Pharmaceuticals is a clinical stage biopharmaceutical company focusing on the development and commercialization of targeted therapeutics in the fields of immuno-inflammation, dermatology and immuno-oncology. Co.'s primary product candidate, bertilimumab, is a human antibody, which targets eotaxin-1, a key regulator of immuno-inflammation. NanoCyclo is a topical nanocapsule formulation of cyclosporine-A, for the treatment of atopic dermatitis and psoriasis. Co.'s pain programs also include AmiKet™ / AmiKet Nano, a prescription topical analgesic cream, and LidoPAIN, an adhesive-backed, lidocaine-based patch for the treatment of lower back pain. We show 7 historical shares outstanding datapoints in our IMNP shares outstanding history coverage, used to compute IMNP market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing IMNP market cap history over the course of time is important for investors
interested in comparing IMNP's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of IMNP versus a peer is one thing; comparing
IMNP market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like IMNP can fluctuate over the course of history.
With this page we aim to empower investors researching IMNP by allowing them to research the IMNP market cap history. |
Free IMNP Email Alerts:
Video: The Importance of Market Cap
